PHOENIX, Oct. 12, 2021 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings Inc. announced today proof of concept data demonstrating the ability of its next generation ImmCelz™ immunotherapy product to "reprogram" patient immune cells using the Company's patent pending "ex vivo cell-free" reprogramming protocol.
The study was performed at cGMP Advanced Cell and Biologic Products Manufacturing Facility of the Diabetes Research Institute, Cell Transplant Center at the University of Miami, Miami FL and was supported by The Cure Alliance, a non-profit research organization.
ImmCelz™, which is protected by trade secrets and published US patents, utilizes adult stem cells derived from qualified donors, to endow specific properties to patient immune cells. After the patient immune cells are incubated with our cell-free reprogramming cocktail, the immune cells are extracted and re-injected back into the patient. These "reprogrammed cells" subsequently "educate" other cells of the immune system to stop attacking the body, while preserving the ability to attack cancers and foreign pathogens.
The ability to use cell-free reprogramming is a giant leap for using patient specific immune therapies. "The data disclosed today, suggest the ability of ImmCelz™ to achieve superior results in a manner which is amenable to safe, scalable and rapid clinical translation," said Dr. Camillo Ricordi, member of the Company's Scientific Advisory Board and Director of the Diabetes Research Institute.
"Immunotherapy represents a revolution in medicine in which cells of the immune system are being developed as drugs," said Timothy Warbington, President and CEO of the Company. "While the majority of efforts are focused on stimulation of immunity, for treatment of cancer and viruses, our ImmCelz™ product represents a novel platform aimed at selective suppression of harmful immune responses."
ImmCelz™ has been demonstrated effective in animal models of autoimmunity and is currently the subject of a pending IND filed by the Company with the FDA for the treatment of stroke victims.
Harmful immune responses, otherwise known as autoimmunity, are a multibillion dollar market which comprises conditions such as type 1 diabetes, stroke, rheumatoid arthritis, kidney and liver disease and potentially many other indications.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in immunotherapy, neurology, urology and orthopedics and is currently listed on the OTC under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com .
F orward-Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
View original content to download multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-reports-positive-data-on-immcelz-immunotherapy-product-301397884.html
SOURCE Creative Medical Technology Holdings, Inc.